ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / TYRA / news
GPCR (27) OCUL (24) ETON (57) PCRX (65) ⌘ Pro Terminal →

Why TYRA Stock advanced +1.23% Today — RQD Quant Desk Flash

$21.33 +1.23% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $21.34

Tyra Biosciences Inc. (TYRA) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.47B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on TYRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is TYRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Tyra Biosciences Inc. (NASDAQ: TYRA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $21.33 (+1.23% 1D, market cap $1.47B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TYRA ranks #787 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does TYRA compare to GPCR and OCUL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TYRA carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GPCR (Structure Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -19.5%, cap $1.46B) and OCUL (Ocular Therapeutix Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.48B). Among the 5-stock peer group, TYRA leads on earnings multiple (N/A) while PCRX leads on capital efficiency (1.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for TYRA?
▼

Per TYRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001863127), Tyra Biosciences Inc. generated $371.7M in revenue (+27.4% YoY), -$119.9M in net income, and -$95.3M in free cash flow against $282.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $21.34 (+0.03%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (7)Whales (5)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$43 Bull$19 Base$15 Bear
📬 FREE TYRA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TYRA)Realized 20D OHLCV Swing Band: ±8.9%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY TYRA SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
22
Grade E$18.70+10.2% Next Q
Q2 (-2Q)
25
Grade E$20.60+5.6% Next Q
Q3 (-1Q)
27
Grade E$21.75-1.9% Next Q
Current
30
Grade E$21.33-9.6% Hist 90D α
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a TYRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While TYRA currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($22.37) and Max Pain ($22.40) forces dealer call-delta covering toward $42.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $TYRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TYRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why TYRA Stock advanced +1.23% Today — RQD Quant Desk Flash

Tyra Biosciences Inc. (TYRA) advanced +1.23% to $21.33, trading at 29% of its 52-week range ($13.35 – $40.65). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 29% of its 52-week range ($13.35 – $40.65) with RSI-14 at 50.8 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±8.9% around $21.33 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live TYRA Headlines & Catalysts
MARKET WIREBenzinga • 13d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session

Gainers Biohaven (NYSE:BHVN) shares increased by 39.3% to $16.37 during Thursday's pre-market session. The company's market cap stands at $1.7 billion. Vogenx (NASDAQ:VOGX) stock rose 22.05% to $24.89. The

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TYRA)

  • ✓Walkthrough of TYRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
TYRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.14%⚡ TESTING RESISTANCE
2026-11-04O $21.07H $21.33L $21.07C $21.33VOL 539.4K
RES: $21.61SUP: $18.00SMA50: $22.37SMA200: $29.76
$38.60$33.09$27.57$22.05$16.54RES $21.61SUP $18.00$21.332026-05-052026-06-182026-08-052026-09-212026-11-04
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

TYRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 TYRA Butterfly Map → + Track TYRA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +27.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on TYRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for TYRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TYRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TYRA)

Health Care Rank #787 of 1015 ⚔️ GPCR vs TYRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (TYRA vs. GPCR, OCUL, ETON, PCRX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Tyra Biosciences Inc. (TYRA) ranks #787 by composite RQD confidence (30/100, grade E) and #298 by equity capitalization ($1.47B). Within this direct 5-issuer industry benchmark cohort, TYRA leads on earnings valuation at N/A trailing P/E, while PCRX leads on capital efficiency and profitability with 1.7% ROIC and 79.4% gross margin. PCRX currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with TYRA at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
TYRA ACTIVE
Tyra Biosciences Inc.
E 30/100 — — -35.0% +1.23% $1.47B Benchmark Subject
GPCR
Structure Therapeutics Inc.
E 27/100 — — -19.5% -6.40% $1.46B /gpcr-vs-tyra →
OCUL
Ocular Therapeutix Inc.
E 24/100 — 87.3% -35.0% -3.44% $1.48B /ocul-vs-tyra →
ETON
Eton Pharmaceuticals Inc.
D+ 57/100 — 53.5% -0.9% -2.63% $1.45B /eton-vs-tyra →
PCRX
Pacira BioSciences Inc.
C 65/100 — 79.4% 1.7% +0.03% $1.45B /pcrx-vs-tyra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001863127 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Tyra Biosciences Inc. (TYRA) reported GAAP revenue of $371.7M (+27.4% vs. FY2024 revenue of $291.7M , and +66.1% cumulative change since FY2023) , GAAP net income of -$119.9M, operating cash flow of -$95.1M, and free cash flow of -$95.3M (-35.3% YoY). On the balance sheet, TYRA closed FY2025 with $282.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $371.7M -$119.9M -$95.1M -$95.3M $282.6M —
FY2024 (FY) 2024-12-31 $291.7M -$86.5M -$69.8M -$70.4M $363.6M —
FY2023 (FY) 2023-12-31 $223.8M -$69.1M -$50.1M -$50.1M — —

3. TYRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is TYRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Tyra Biosciences Inc. (NASDAQ: TYRA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $21.33 (+1.23% 1D, market cap $1.47B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 5/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, TYRA ranks #787 in composite RQD confidence.

How does TYRA compare to GPCR and OCUL in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), TYRA carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GPCR (Structure Therapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -19.5%, cap $1.46B) and OCUL (Ocular Therapeutix Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $1.48B). Among the 5-stock peer group, TYRA leads on earnings multiple (N/A) while PCRX leads on capital efficiency (1.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for TYRA?

Per TYRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001863127), Tyra Biosciences Inc. generated $371.7M in revenue (+27.4% YoY), -$119.9M in net income, and -$95.3M in free cash flow against $282.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is TYRA trading relative to its 50-day, 200-day, and 52-week technical levels?

TYRA last traded at $21.33 (+1.23% on volume of 539,392 shares), positioning the stock -4.65% below its 50-day simple moving average ($22.37) and -28.33% below its 200-day simple moving average ($29.76). Across its 52-week range of $13.35 to $40.65, TYRA sits at the 29.2% percentile with a 14-day RSI of 50.8 (NEUTRAL RANGE) and an implied next-earnings move of ±8.9% ($19.43 to $23.23).

Direct Sub-Reports: TYRA RQD Cockpit TYRA 12M Forecast TYRA Earnings & Move TYRA Dividends & DRIP TYRA Insiders & 13F TYRA Whale Options TYRA Profit Sankey TYRA News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

TYRA — Tyra Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Tyra Biosciences Inc. (TYRA) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $21.33 (+1.23% 1D, market capitalization $1.47B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -6.45%.
  • Whale 13F & Options Flow (5/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

. Is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Revenue is reported as — across all listed periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Tyra Biosciences Inc. (TYRA) reported $371.7M in annual revenue (up from $291.7M in FY2024, +27.4% YoY) and -$119.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($223.8M revenue, -$69.1M net income) through FY2025, TYRA scaled operating cash flow to -$95.1M and free cash flow to -$95.3M, backed by $282.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -6.45% and institutional whale pillar of 5/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 5/20, sustained execution supports upside toward the upper end of the $13.35 – $40.65 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data.

  • Key Question #1: Can TYRA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $371.7M and free cash flow of -$95.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is TYRA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

TYRA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Tyra Biosciences Inc. (TYRA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to TYRA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

TYRA Bull vs. Bear Conversation Board — What's Your Call at $21.33?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON TYRA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on TYRA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $27.18 (+29.0%)
📌 Pinned Debate

Shares trade with a beta of 1.0 and a 52-week range of $13.35 to $40.65, and the most recent news items carry GREEN CATALYST tags.

The street is overcomplicating Tyra Biosciences Inc. (TYRA). Shares trade with a beta of 1.0 and a 52-week range of $13.35 to $40.65, and the most recent news items carry GREEN CATALYST tags.. With an RQD score of 30/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $22.76.

CapAlloc_Nerd 🐂 BULL

@AlphaFlow_Cap Agree on the RQD 30/100 quality, though with 1.0 beta I'm scaling in with half-size at $21.07 and keeping dry powder in case we test $19.60.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $15.80 (-25.0%)
Spot @ $21.07

Negative ROIC of -35%, negative FCF yield of -6.45%, and FY 2025 operating loss of -$132.8M against $0.0M revenue show the business is

Sitting on the sidelines or leaning short TYRA above $21.07. Negative ROIC of -35%, negative FCF yield of -6.45%, and FY 2025 operating loss of -$132.8M against $0.0M revenue show the business is not yet self-funding.. Until Fundamental Cash Engine (7/20) and FCF yield (-6.45%) inflect higher, upside is capped near $40.65.

LIVE TAPE